Pharmaceutical

Target ALS and Modality.AI Collaborate in Multimodal Study of ALS

Direct-to-participant study to reach 150 people living with ALS, with 2 participants already enrolled. NEW YORK, Sept. 26, 2024 /PRNewswire/…

4 months ago

Cleanroom Technologies Market to Hit USD 12.3 Billion by 2029 with 6.9% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Sept. 26, 2024 /PRNewswire/ -- The global cleanroom technologies market is set to grow from USD 8.8 billion…

4 months ago

Coronado Research announce appointment of Gail Kniveton to Chief Talent Officer role

LONDON, Sept. 26, 2024 /PRNewswire/ -- Coronado Research announced today that Gail Kniveton has been appointed as Chief Talent Officer.…

4 months ago

Rovia Clinical Research Launches as Parent Company to East Coast Institute for Research, Universal Axon Clinical Research, and IMIC Inc. Clinical Research Center

JACKSONVILLE, Fla., Sept. 26, 2024 /PRNewswire/ -- Rovia Clinical Research is excited to announce the creation of its clinical research…

4 months ago

LUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH

MINNEAPOLIS , Sept. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, Lunaphore,…

4 months ago

PharmaCord Announces Completion of Permira Investment

Investment will enable PharmaCord to accelerate its technology roadmap and expand into additional commercialization service lines for its life sciences…

4 months ago

Sunshine Biopharma Launches Two New Generic Prescription Drugs

FORT LAUDERDALE, FL / ACCESSWIRE / September 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…

4 months ago

Fortress Biotech to Participate in October 2024 Investor Conferences

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring…

4 months ago

Interim results for the six months ended June 30, 2024

September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024…

4 months ago